Preventive effects of the angiotensin‑converting enzyme inhibitor, captopril, on the development of azoxymethane‑induced colonic preneoplastic lesions in diabetic and hypertensive rats

Kochi,Takahiro; Shimizu,Masahito; Ohno,Tomohiko; Baba,Atsushi; Sumi,Takafumi; Kubota,Masaya; Shirakami,Yohei; Tsurumi,Hisashi; Tanaka,Takuji; Moriwaki,Hisataka

doi:10.3892/ol.2014.2136

Preventive effects of the angiotensin‑converting enzyme inhibitor, captopril, on the development of azoxymethane‑induced colonic preneoplastic lesions in diabetic and hypertensive rats

Authors:
- Takahiro Kochi
- Masahito Shimizu
- Tomohiko Ohno
- Atsushi Baba
- Takafumi Sumi
- Masaya Kubota
- Yohei Shirakami
- Hisashi Tsurumi
- Takuji Tanaka
- Hisataka Moriwaki
View Affiliations

Affiliations: Department of Medicine/Gastroenterology, Gifu University Graduate School of Medicine, Gifu, Chūbu 501‑1194, Japan, Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, Chūbu 501‑1194, Japan
Published online on: May 12, 2014 https://doi.org/10.3892/ol.2014.2136
Pages: 223-229

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metabolic syndrome (Mets), including diabetes and hypertension, increases the risk of colorectal cancer via the induction of chronic inflammation, acceleration of oxidative stress, and activation of the renin‑angiotensin system. The present study examined the possible inhibitory effects of captopril, an angiotensin‑converting enzyme (ACE) inhibitor and antihypertensive drug, on the development of azoxymethane (AOM)‑induced colonic premalignant lesions, aberrant crypt foci (ACF), in SHRSP.Z‑Leprfa/IzmDmcr (SHRSP‑ZF) diabetic and hypertensive rats. Male 6‑week‑old SHRSP‑ZF rats were administered two, weekly intraperitoneal injections of AOM (20 mg/kg body weight). Following the second injection, the rats received drinking water containing captopril (8 mg/kg/day) for two weeks. At sacrifice, captopril administration significantly lowered the blood pressure and reduced the total number and size of ACF compared with those observed in the untreated group. The serum levels of angiotensin‑II and the expression levels of ACE and angiotensin‑II type 1 receptor mRNA on the colonic mucosa decreased following captopril treatment. Captopril also reduced the urinary 8‑hydroxy‑2'‑deoxyguanosine levels and the serum derivatives of reactive oxygen metabolites levels, both of which are oxidative stress markers, but increased the mRNA levels of catalase, an antioxidant enzyme, in the colonic epithelium. Moreover, the expression levels of tumor necrosis factor‑α, interleukin‑18, monocyte chemoattractant protein‑1, inducible nitric oxide synthase, vascular endothelial growth factor and proliferating cell nuclear antigen mRNA in the colonic epithelium were decreased significantly following captopril administration. These observations suggested that captopril prevents the development of ACF by inhibiting renin‑angiotensin system activation and attenuating inflammation and oxidative stress in SHRSP‑ZF rats. Therefore, targeting Mets‑related pathophysiological conditions, including renin‑angiotensin system activation, may be an effective strategy to prevent colorectal carcinogenesis in patients with Mets, particularly those with hypertension.

View Figures

View References

1	Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD and Folsom AR: The metabolic syndrome and risk of incident colorectal cancer. Cancer. 107:28–36. 2006.
2	Stocks T, Van Hemelrijck M, Manjer J, et al: Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension. 59:802–810. 2012.
3	Ishino K, Mutoh M, Totsuka Y and Nakagama H: Metabolic syndrome: A novel high-risk state for colorectal cancer. Cancer Lett. 2012.
4	Shimizu M, Kubota M, Tanaka T and Moriwaki H: Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci. 13:579–595. 2012.
5	Donohoe CL, Pidgeon GP, Lysaght J and Reynolds JV: Obesity and gastrointestinal cancer. Br J Surg. 97:628–642. 2010.
6	Shimizu M, Shirakami Y, Iwasa J, et al: Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin Cancer Res. 15:3068–3075. 2009.
7	Shimizu M, Shirakami Y, Sakai H, et al: (−)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res (Phila). 1:298–304. 2008.
8	Kubota M, Shimizu M, Sakai H, et al: Preventive effects of curcumin on the development of azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db obese mice. Nutr Cancer. 64:72–79. 2012.
9	Yasuda Y, Shimizu M, Shirakami Y, et al: Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci. 101:1701–1707. 2010.
10	Kochi T, Shimizu M, Ohno T, et al: Enhanced development of azoxymethane-induced colonic preneoplastic lesions in hypertensive rats. Int J Mol Sci. 14:14700–14711. 2013.
11	de Kloet AD, Krause EG and Woods SC: The renin angiotensin system and the metabolic syndrome. Physiol Behav. 100:525–534. 2010.
12	Chrysant SG, Chrysant GS, Chrysant C and Shiraz M: The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade. Curr Clin Pharmacol. 5:89–95. 2010.
13	Fyhrquist F and Saijonmaa O: Renin-angiotensin system revisited. J Intern Med. 264:224–236. 2008.
14	Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 362:782–788. 2003.
15	van Vark LC, Bertrand M, Akkerhuis KM, et al: Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 33:2088–2097. 2012.
16	Deshayes F and Nahmias C: Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 16:293–299. 2005.
17	George AJ, Thomas WG and Hannan RD: The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 10:745–759. 2010.
18	Ager EI, Neo J and Christophi C: The renin-angiotensin system and malignancy. Carcinogenesis. 29:1675–1684. 2008.
19	Bernardi S, Zennaro C, Palmisano S, et al: Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. J Renin Angiotensin Aldosterone Syst. 13:202–209. 2012.
20	Hiraoka-Yamamoto J, Nara Y, Yasui N, et al: Establishment of a new animal model of metabolic syndrome: SHRSP fatty (fa/fa) rats. Clin Exp Pharmacol Physiol. 31:107–109. 2004.
21	Ueno T, Takagi H, Fukuda N, et al: Cardiovascular remodeling and metabolic abnormalities in SHRSP. Z-Lepr(fa)/IzmDmcr rats as a new model of metabolic syndrome. Hypertens Res. 31:1021–1031. 2008.
22	Kubota M, Shimizu M, Sakai H, et al: Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Biochem Biophys Res Commun. 410:108–113. 2011.
23	Ogawa K, Hara T, Shimizu M, et al: Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase. Cancer Sci. 103:951–958. 2012.
24	Suzuki Y, Imai K, Takai K, et al: Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: A prospective case series study using the d-ROM test. J Cancer Res Clin Oncol. in press. 2013.
25	Tamarat R, Silvestre JS, Durie M and Levy BI: Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest. 82:747–756. 2002.
26	Chen H, Sullivan G, Yue LQ, Katz A and Quon MJ: QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am J Physiol Endocrinol Metab. 284:E804–812. 2003.
27	Shimomoto T, Ohmori H, Luo Y, et al: Diabetes-associated angiotensin activation enhances liver metastasis of colon cancer. Clin Exp Metastasis. 29:915–925. 2012.
28	Kedika R, Patel M, Pena Sahdala HN, et al: Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol. 45:e12–16. 2011.
29	Cassis P, Conti S, Remuzzi G and Benigni A: Angiotensin receptors as determinants of life span. Pflugers Arch. 459:325–332. 2010.
30	Tudek B and Speina E: Oxidatively damaged DNA and its repair in colon carcinogenesis. Mutat Res. 736:82–92. 2012.
31	Valavanidis A, Vlachogianni T and Fiotakis C: 8-hydroxy-2′-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 27:120–139. 2009.
32	Uemura H, Ishiguro H, Ishiguro Y, Hoshino K, Takahashi S and Kubota Y: Angiotensin II induces oxidative stress in prostate cancer. Mol Cancer Res. 6:250–258. 2008.
33	Smith GR and Missailidis S: Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond). 1:32004.
34	Yvan-Charvet L, Massiera F, Lamande N, et al: Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology. 150:1421–1428. 2009.